



**SERES**  
THERAPEUTICS™

## Seres Therapeutics to Present at the 2016 UBS Healthcare Conference

May 17, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will present at the UBS Global Healthcare Conference on Tuesday, May 24. The presentation will take place at the Grand Hyatt Hotel in New York, NY at 8:30 a.m. ET.

Live audio webcast will be available under the Investors and Media section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

### About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres' most advanced program, SER-109, has successfully completed a Phase 1b/2 study demonstrating a clinical benefit in patients with recurring *Clostridium difficile* infection (CDI) and is currently being evaluated in a Phase 2 study in recurring CDI. The FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. Seres' second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com). Follow us on Twitter @SeresTx.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20160517005598/en/>

Source: Seres Therapeutics

### IR and PR Contact:

Seres Therapeutics

Carlo Tanzi, Ph.D., 617-203-3467

Head of Investor Relations and Corporate Communications

[Ctanzi@serestherapeutics.com](mailto:Ctanzi@serestherapeutics.com)